Nonparalytic botulinum molecules for the control of pain

Pain

Volumn 157, Issue 5, 2016, Pages 1045-1055

  Mangione, Antonina S ^a,b   Obara, Ilona ^c   Maiarú, Maria ^a   Geranton, Sandrine M ^a   Tassorelli, Cristina ^b,d   Ferrari, Enrico ^e   Leese, Charlotte ^f   Davletov, Bazbek ^e   Hunt, Stephen P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^c DURHAM UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF PAVIA   (Italy)

^e UNIVERSITY OF LINCOLN   (United Kingdom)

^f UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Anti nociception; BiTox; Botulinum toxin; Inflammatory pain; Neuropathic pain

Indexed keywords

BOTULINUM TOXIN A; CAPSAICIN; EVANS BLUE; FORMALDEHYDE; FREUND ADJUVANT; PROTEIN C FOS; MUSCLE RELAXANT AGENT;

ACETONE TEST; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DORSAL ROOT; DRUG EFFECT; EDEMA; EXTRAVASATION; FORMALIN TEST; HYPERALGESIA; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INCISION; INFLAMMATORY PAIN; INTRAPLANTAR DRUG ADMINISTRATION; KERATINOCYTE; MALE; MECHANICAL HYPERALGESIA; MOTOR PERFORMANCE; NERVE CELL; NERVE FIBER C; NERVE INJURY; NEUROPATHIC PAIN; NOCICEPTIVE STIMULATION; NONHUMAN; PAIN RECEPTOR; PAIN THRESHOLD; PINPRICK TEST; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPINAL CORD DORSAL HORN; THERMAL STIMULATION; TREATMENT OUTCOME; VON FREY TEST; ANIMAL; CELL COUNT; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; INFLAMMATION; METABOLISM; MOTOR ACTIVITY; NEURALGIA; NONMYELINATED NERVE; PAIN MEASUREMENT; PAIN, POSTOPERATIVE; PATHOLOGY; PATHOPHYSIOLOGY; SPINAL GANGLION; SPRAGUE DAWLEY RAT;

ANIMALS; BOTULINUM TOXINS, TYPE A; CAPSAICIN; CELL COUNT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FREUND'S ADJUVANT; GANGLIA, SPINAL; HYPERALGESIA; INFLAMMATION; KERATINOCYTES; MALE; MOTOR ACTIVITY; NERVE FIBERS, UNMYELINATED; NEURALGIA; NEUROMUSCULAR AGENTS; PAIN MEASUREMENT; PAIN THRESHOLD; PAIN, POSTOPERATIVE; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD DORSAL HORN;

EID: 84964699600     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1097/j.pain.0000000000000478     Document Type: Article

References (50)

1. Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M. Longdistance retrograde effects of botulinum neurotoxin A. J Neurosci 2008; 28: 3689-96
2. Bach-Rojecky L, Dominis M, Lackovic Z. Lack of anti-inflammatory effect of botulinum toxin type A in experimental models of inflammation. Fundam Clin Pharmacol 2008; 22: 503-9
3. Binz T, Sikorra S, Mahrhold S. Clostridial neurotoxins: mechanism of SNARE cleavage and outlook on potential substrate specificity reengineering. Toxins (Basel) 2010; 2: 665-82
4. Brennan TJ. Pathophysiology of postoperative pain. PAIN 2011; 152(3 suppl): S33-40
5. Chen F, Foran P, Shone CC, Foster KA, Melling J, Dolly JO. Botulinum neurotoxin B inhibits insulin-stimulated glucose uptake into 3T3-L1 adipocytes and cleaves cellubrevin unlike type A toxin which failed to proteolyze the SNAP-23 present. Biochemistry 1997; 36: 5719-28
6. Darios F, Niranjan D, Ferrari E, Zhang F, Soloviev M, Rummel A, Bigalke H, Suckling J, Ushkaryov Y, Naumenko N, Shakirzyanova A, Giniatullin R, Maywood E, Hastings M, Binz T, Davletov B. SNARE tagging allows stepwise assembly of a multimodular medicinal toxin. Proc Natl Acad Sci U S A 2010; 107: 18197-201
7. Dawes JM, Antunes-Martins A, Perkins JR, Paterson KJ, Sisignano M, Schmid R, Rust W, Hildebrandt T, Geisslinger G, Orengo C, Bennett DL, McMahon SB. Genome-wide transcriptional profiling of skin and dorsal root ganglia after ultraviolet-B-induced inflammation. PLoS One 2014; 9: e93338
8. Decosterd I, Woolf CJ. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. PAIN 2000; 87: 149-58
9. Djouhri L, Koutsikou S, Fang X, McMullan S, Lawson SN. Spontaneous pain, both neuropathic and inflammatory, is related to frequency of spontaneous firing in intact C-fiber nociceptors. J Neurosci 2006; 26: 1281-92
10. Dolly JO, Aoki KR. The structure and mode of action of different botulinum toxins. Eur J Neurol 2006; 13(suppl 4): 1-9
11. Ferrari E, Gu C, Niranjan D, Restani L, Rasetti-Escargueil C, Obara I, Geranton SM, Arsenault J, Goetze TA, Harper CB, Nguyen TH, Maywood E, OBrien J, Schiavo G, Wheeler DW, Meunier FA, Hastings M, Edwardson JM, Sesardic D, Caleo M, Hunt SP, Davletov B. Synthetic self-Assembling clostridial chimera for modulation of sensory functions. Bioconjug Chem 2013; 24: 1750-9
12. Ferrari E, Maywood ES, Restani L, Caleo M, Pirazzini M, Rossetto O, Hastings MH, Niranjan D, Schiavo G, Davletov B. Re-Assembled botulinum neurotoxin inhibits CNS functions without systemic toxicity. Toxins (Basel) 2011; 3: 345-55
13. Ferrari E, Soloviev M, Niranjan D, Arsenault J, Gu C, Vallis Y, OBrien J, Davletov B. Assembly of protein building blocks using a short synthetic peptide. Bioconjug Chem 2012; 23: 479-84
14. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpaa M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, RowbothamM, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-Analysis. Lancet Neurol 2015; 14: 162-73
15. Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology 2001; 56: 1290-3
16. Gazerani P, Pedersen NS, Drewes AM, Arendt-Nielsen L. Botulinum toxin type A reduces histamine-induced itch and vasomotor responses in human skin. Br J Dermatol 2009; 161: 737-45
17. Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen L. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. PAIN 2009; 141: 60-9
18. Geppetti P, Nassini R, Materazzi S, Benemei S. The concept of neurogenic inflammation. BJU Int 2008; 101(suppl 3): 2-6
19. Geranton SM, Jimenez-Diaz L, Torsney C, Tochiki KK, Stuart SA, Leith JL, Lumb BM, Hunt SP. A rapamycin-sensitive signaling pathway is essential for the full expression of persistent pain states. J Neurosci 2009; 29: 15017-27
20. Gold MS, Gebhart GF. Nociceptor sensitization in pain pathogenesis. Nat Med 2010; 16: 1248-57
21. Hepp R, Puri N, Hohenstein AC, Crawford GL, Whiteheart SW, Roche PA. Phosphorylation of SNAP-23 regulates exocytosis from mast cells. J Biol Chem 2005; 280: 6610-20
22. Hsieh ST, Lin WM. Modulation of keratinocyte proliferation by skin innervation. J Invest Dermatol 1999; 113: 579-86
23. Huang IT, Lin WM, Shun CT, Hsieh ST. Influence of cutaneous nerves on keratinocyte proliferation and epidermal thickness in mice. Neuroscience 1999; 94: 965-73
24. Hunt SP, Pini A, Evan G. Induction of c-fos-like protein in spinal cord neurons following sensory stimulation. Nature 1987; 328: 632-4
25. Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-Analysis. JAMA 2012; 307: 1736-45
26. Jimenez-Diaz L, Geranton SM, Passmore GM, Leith JL, Fisher AS, Berliocchi L, Sivasubramaniam AK, Sheasby A, Lumb BM, Hunt SP. Local translation in primary afferent fibers regulates nociception. PLoS One 2008; 3: e1961
27. Kramer HH, Angerer C, Erbguth F, Schmelz M, Birklein F. Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol 2003; 250: 188-93
28. Magerl W, Fuchs PN, Meyer RA, Treede RD. Roles of capsaicininsensitive nociceptors in cutaneous pain and secondary hyperalgesia. Brain 2001; 124: 1754-64
29. Matak I, Bach-Rojecky L, Filipovic B, Lackovic Z. Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience 2011; 186: 201-7
30. Matak I, Lackovic Z. Botulinum toxin A, brain and pain. Prog Neurobiol 2014; 119-120: 39-59
31. Meunier FA, SchiavoG, Molgo J. Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J Physiol Paris 2002; 96: 105-13
32. Montal M. Botulinum neurotoxin: a marvel of protein design. Annu Rev Biochem 2010; 79: 591-617
33. Obara I, Geranton SM, Hunt SP. Axonal protein synthesis: a potential target for pain relief?. Curr Opin Pharmacol 2012; 12: 42-8
34. Obara I, Tochiki KK, Geranton SM, Carr FB, Lumb BM, Liu Q, Hunt SP. Systemic inhibition of the mammalian target of rapamycin (mTOR) pathway reduces neuropathic pain in mice. PAIN 2011; 152: 2582-95
35. Paterson K, Lolignier S, Wood JN, McMahon SB, Bennett DL. Botulinum toxin-A treatment reduces human mechanical pain sensitivity and mechanotransduction. Ann Neurol 2014; 75: 591-6
36. Price TJ, Geranton SM. Translating nociceptor sensitivity: the role of axonal protein synthesis in nociceptor physiology. Eur J Neurosci 2009; 29: 2253-63
37. Puri N, Roche PA. Ternary SNARE complexes are enriched in lipid rafts during mast cell exocytosis. Traffic 2006; 7: 1482-94
38. Purkiss J, Welch M, Doward S, Foster K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol 2000; 59: 1403-6
39. Ramachandran R, Yaksh TL. Therapeutic use of botulinum toxin in migraine: mechanisms of action. Br J Pharmacol 2014; 171: 4177-92
40. Restani L, Antonucci F, Gianfranceschi L, Rossi C, Rossetto O, Caleo M. Evidence for anterograde transport and transcytosis of botulinum neurotoxin A (BoNT/A). J Neurosci 2011; 31: 15650-9
41. Roggenkamp D, Kopnick S, Stab F, Wenck H, Schmelz M, Neufang G. Epidermal nerve fibers modulate keratinocyte growth via neuropeptide signaling in an innervated skin model. J Invest Dermatol 2013; 133: 1620-8
42. Salinas S, Schiavo G, Kremer EJ. A hitchhikers guide to the nervous system: the complex journey of viruses and toxins. Nat Rev Microbiol 2010; 8: 645-55
43. Sauer RS, Hackel D, Morschel L, Sahlbach H, Wang Y, Mousa SA, Roewer N, Brack A, Rittner HL. Toll like receptor (TLR)-4 as a regulator of peripheral endogenous opioid-mediated analgesia in inflammation. Mol Pain 2014; 10: 10
44. Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 2000; 80: 717-66
45. Stein C, Schafer M, Machelska H. Attacking pain at its source: new perspectives on opioids. Nat Med 2003; 9: 1003-8
46. Tjolsen A, Berge OG, Hunskaar S, Rosland JH, Hole K. The formalin test: an evaluation of the method. PAIN 1992; 51: 5-17
47. Tugnoli V, Capone JG, Eleopra R, Quatrale R, Sensi M, Gastaldo E, Tola MR, Geppetti P. Botulinum toxin type A reduces capsaicinevoked pain and neurogenic vasodilatation in human skin. PAIN 2007; 130: 76-83
48. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000; 38: 245-58
49. Xiao L, Cheng J, Zhuang Y, Qu W, Muir J, Liang H, Zhang D. Botulinum toxin type A reduces hyperalgesia and TRPV1 expression in rats with neuropathic pain. Pain Med 2013; 14: 276-86
50. Yuan RY, Sheu JJ, Yu JM, Chen WT, Tseng IJ, Chang HH, Hu CJ. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 2009; 72: 1473-8